Search Patents
  • 3CLPRO-TARGETING PHILLYRIN, DERIVATIVE THEREOF, AND USE THEREOF AGAINST NOVEL CORONAVIRUS
    Publication number: 20230101803
    Abstract: The present invention provides a use of a phillyrin/phillygenin composition which targets and inhibits 3CLpro protein of COVID-19 virus, in preparation of an anti-coronavirus drug or a drug for treating a disease caused by the coronavirus, wherein the coronavirus is COVID-19 virus, and the disease caused by the coronavirus is COVID-19.
    Type: Application
    Filed: February 9, 2021
    Publication date: March 30, 2023
    Inventors: Zifeng YANG, Li FU, Ge JIANG, Nanshan ZHONG, Wei YANG, Qinhai MA, Min HUI, Chufang LI, Shuo WANG, Weiyi PAN, Qi LU, Aiai SONG, Jirui HOU, Runfeng LI, Mingming LU, Yingping WANG, Yang LIU, Guoyou LIU, Wenfei FU, Xue FENG, Qingfeng ZHOU, Xiaofeng YI, Rongxin LIN, Yu ZHANG
  • CORONAVIRUS VACCINE
    Publication number: 20230075979
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: March 18, 2022
    Publication date: March 9, 2023
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • DRUG FOR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CAUSED BY CORONAVIRUS AND COMPLICATIONS THEREOF AND USE OF THE DRUG
    Publication number: 20230135239
    Abstract: The present invention discloses a drug for treating severe acute respiratory syndrome caused by coronavirus and the complications thereof and the use of the drug, and specifically the use of an agent in the preparation of a drug for treating severe acute respiratory syndrome caused by coronavirus and the complications thereof. The above-mentioned agent is at least one of hyaluronic acid synthesis inhibitor, hyaluronidase, hyaluronidase inhibitor, hyaluronic acid receptor inhibitor, and anticoagulant.
    Type: Application
    Filed: November 4, 2021
    Publication date: May 4, 2023
    Applicants: SHANGHAI PUBLIC HEALTH CLINICAL CENTER, Shanghai Yizhe Biotechnology Co., Ltd.
    Inventors: Wenqiang YU, Zhenyan LI, Jianqing XU, Wei LI, Cheng LIAN
  • METHOD FOR INHIBITING CORONAVIRUS INFECTION AND REPLICATION
    Publication number: 20210386725
    Abstract: Disclosed herein is a method for inhibiting coronavirus infection, including administering to a subject in need thereof an effective amount of pioglitazone or a pharmaceutically acceptable salt thereof. Also disclosed is a method for inhibiting coronavirus replication, including contacting a coronavirus with pioglitazone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 28, 2020
    Publication date: December 16, 2021
    Inventors: Shin-Ru SHIH, Yu-An KUNG, Huan-Jung CHIANG, Chuan-Tien HUNG, Yu-Nong GONG, Hsin-Ping CHIU, Chiung-Guei HUANG, Peng-Nien HUANG, Sheng-Yu HUANG
  • Methods of using probenecid for treatment of coronavirus infections
    Patent number: 11116737
    Abstract: Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: September 14, 2021
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Ralph A. Tripp, Jackelyn Murray, Robert Jeff Hogan
  • CORONAVIRUS VACCINE
    Publication number: 20240075165
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 7, 2024
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • METHOD FOR INHIBITING CORONAVIRUS INFECTION AND REPLICATION
    Publication number: 20210386726
    Abstract: Disclosed herein is a method for inhibiting coronavirus infection, including administering to a subject in need thereof an effective amount of rosiglitazone or a pharmaceutically acceptable salt thereof. Also disclosed is a method for inhibiting coronavirus replication, including contacting a coronavirus with rosiglitazone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 28, 2020
    Publication date: December 16, 2021
    Inventors: Shin-Ru SHIH, Yu-An KUNG, Huan-Jung CHIANG, Chuan-Tien HUNG, Yu-Nong GONG, Hsin-Ping CHIU, Chiung-Guei HUANG, Peng-Nien HUANG, Sheng-Yu HUANG
  • CORONAVIRUS VACCINE
    Publication number: 20230073461
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: March 18, 2022
    Publication date: March 9, 2023
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • Coronavirus vaccine
    Patent number: 11547673
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: January 10, 2023
    Assignee: BioNTech SE
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • DIAGNOSIS, PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION
    Publication number: 20230203103
    Abstract: The invention relates to coronavirus peptides, and the use of such peptides for the diagnosis, treatment and prevention of coronavirus infection.
    Type: Application
    Filed: June 2, 2021
    Publication date: June 29, 2023
    Inventors: Thomas RADEMACHER, Richard PERRINS, Laurens RADEMACHER
  • Coronavirus-targeting universal DC cell vaccine, and preparation method and use thereof
    Patent number: 11696949
    Abstract: The present invention provides a method for preparing a coronavirus-targeting universal DC cell vaccine, and belongs to the technical field of virus vaccine preparation. The preparation method includes the following steps: ligating a fusion gene including a HLA gene and a coronavirus antigen gene onto an expression vector to obtain a recombinant vector; then transferring the recombinant vector into antigen-presenting cells to be transfected to obtain the coronavirus-targeting universal DC cell vaccine. The universal DC cell vaccine of the present invention has a targeting property against a coronavirus, can effectively stimulate a CTL, and has a killing effect on a target cell.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: July 11, 2023
    Assignees: Beijing DCTY Biotech Co., Ltd.
    Inventors: Shunchang Jiao, Rong Zhang, Zishan Zhou
  • METHODS FOR TREATING DYSGEUSIA AND OTHER LINGERING SYMPTOMS ASSOCIATED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTIONADN CORONAVIRUS DISEASE 2019
    Publication number: 20240165069
    Abstract: Methods for treating one or more symptoms associated with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or coronavirus disease 2019 (COVID-19), including lingering dysgeusia, by administering a lipoxin analog, such as BLXA4, to a subject in need of treatment, including post-COVID-19 subjects.
    Type: Application
    Filed: February 18, 2022
    Publication date: May 23, 2024
    Inventors: Christopher R. Schuster, Wesley D. Blakeslee
  • USE OF BENZISOSELAZOLE DERIVATIVE FOR ANTI-CORONAVIRUS AND CONTROL OF INTERSTITIAL LUNG DISEASE (ILD) RELATED TO CORONAVIRUS
    Publication number: 20230210819
    Abstract: The benzisoselazole derivative of formula (I) can be used for preparing an anti-coronavirus drug or a drug for treating diseases caused by coronaviruses. The benzisoselazole derivatives can effectively inhibit the activity of 2019-nCoV 3CLpro proteolytic enzyme, thus inhibiting the activation of 2019-nCoV RNA polymerase, inhibiting virus replication, while also effectively treating interstitial lung disease (ILD) caused by coronavirus.
    Type: Application
    Filed: July 6, 2021
    Publication date: July 6, 2023
    Inventors: Huihui ZENG, Hanwei YIN
  • Method of treating coronavirus infections
    Patent number: 11166999
    Abstract: The present application relates to a compositions and methods comprising or expressing a MOMO30 protein derived from Momordica balsamina. The MOMO30 protein is about 30 kDa in size, binds coronavirus S protein, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to coronavirus spike (S) protein, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by a coronavirus or alleviating symptoms in coronavirus infected patients and comprises the amino acid sequence of SEQ ID NO: 1. The MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for preventing or treating viral infections by coronaviruses and others.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: November 9, 2021
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Michael Powell, Erick Vidjin′ Agnih Gbodossou
  • NOVEL CORONAVIRUS ANTIBODY DETECTION KIT BASED ON MAGNETIC PARTICLE CHEMILUMINESCENCE
    Publication number: 20230296601
    Abstract: The present application provides a novel coronavirus antibody detection kit based on magnetic particle chemiluminescence. The detection kit includes: streptavidin magnetic particles, biotin-labeled novel coronavirus antigens, an acridine sulfonamide-labeled secondary antibody, a sample diluent and a quality control material; wherein the biotin-labeled novel coronavirus antigens include a recombinant nucleocapsid protein and a recombinant spike protein S1. The sample to be tested, the biotin-labeled antigens and the streptavidin magnetic particles are mixed, incubated and washed, and then the acridine sulfonamide-labeled antibody is added to form a magnetic particle-streptavidin-biotin-antigen-novel coronavirus antibody-secondary antibody complex, and then the luminous intensity is detected to qualitatively determine the sample to be tested.
    Type: Application
    Filed: March 24, 2021
    Publication date: September 21, 2023
    Inventors: Chunlong Liu, Zhou Zhang, Shaohua Ma, Jiashun Wang, Yan Su, Zeqi Zhou
  • KIT AND METHOD FOR DETECTING CORONAVIRUS
    Publication number: 20230273147
    Abstract: Provided are a kit for detecting Coronavirus using magnetic nanoparticles and a method detecting Coronavirus using the same. The kit for detecting Coronavirus includes a reactor having an opening on one side and provided with a sample containing Coronavirus, at least one magnetic nanoparticle part provided in the reactor, a conductive substrate provided to cover the opening of the reactor, and a magnetic field applying part for applying a magnetic field to the reactor, in which the magnetic nanoparticle part includes a magnetic nanoparticle including a core portion made of iron oxide and a shell portion made of gold and provided to surround the core portion, and a primer attached to the shell portion of the magnetic nanoparticle.
    Type: Application
    Filed: November 4, 2022
    Publication date: August 31, 2023
    Applicants: Korea University Research and Business Foundation, Industry-University Cooperation Foundation Hanyang University ERICA Campus
    Inventors: Young Keun KIM, Ju Hun LEE, Bum Chul PARK, Hyeon Su PARK, Jeong Ook SOH
  • Methods of using probenecid for treatment of coronavirus infections
    Patent number: 11903916
    Abstract: Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: February 20, 2024
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Ralph A. Tripp, Jackelyn Murray, Robert Jeff Hogan
  • METHODS AND SYSTEMS FOR DETECTING CORONAVIRUS
    Publication number: 20220206001
    Abstract: Provided herein are methods and systems for detecting coronavirus. Methods and systems as described herein comprise using antibodies with improved specificity and sensitivity for accurately detecting coronavirus.
    Type: Application
    Filed: October 21, 2021
    Publication date: June 30, 2022
    Inventor: Aaron SATO
  • METHOD OF TREATING CORONAVIRUS INFECTION BY ADMINISTRATION OF ETHYL MERCURY OR THIOL DERIVATIVE THEREOF
    Publication number: 20230398090
    Abstract: Disclosed herein are methods of treating a coronavirus infection by administration of ethyl mercury or thiol derivative thereof in an amount effective to treat the coronavirus infection.
    Type: Application
    Filed: March 24, 2021
    Publication date: December 14, 2023
    Inventor: John McMichael
  • CORONAVIRUS VACCINE COMPOSITIONS, METHODS, AND USES THEREOF
    Publication number: 20220016235
    Abstract: The present disclosure relates in some aspects to immunogenic compositions including recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing a coronavirus infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 20, 2022
    Applicant: Sichuan Clover Biopharmaceuticals, Inc.
    Inventors: Peng LIANG, Joshua LIANG
Narrow Results

Filter by US Classification